AU2001267349A1 - Pharmaceutical preparations comprising modified peptides - Google Patents

Pharmaceutical preparations comprising modified peptides

Info

Publication number
AU2001267349A1
AU2001267349A1 AU2001267349A AU6734901A AU2001267349A1 AU 2001267349 A1 AU2001267349 A1 AU 2001267349A1 AU 2001267349 A AU2001267349 A AU 2001267349A AU 6734901 A AU6734901 A AU 6734901A AU 2001267349 A1 AU2001267349 A1 AU 2001267349A1
Authority
AU
Australia
Prior art keywords
peptidel
amino acid
pharmaceutical preparations
modified peptides
constellation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001267349A
Inventor
Michael Buschle
Frank Mattner
Walter Schmidt
Wolfgang Zauner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CISTEM Biotechnologies GmbH
Original Assignee
CISTEM Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CISTEM Biotechnologies GmbH filed Critical CISTEM Biotechnologies GmbH
Publication of AU2001267349A1 publication Critical patent/AU2001267349A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pharmaceutical preparation comprising a peptide of the formula XN-PeptideL-XM, wherein X is an amino acid residue selected from Gly, Ala, Val, Leu, Ile, Pro, Phe, Tyr, Trp, Cys, Met, Glu and Asp; PeptideL is a potentially immunogenic fragment consisting of L amino acid residues; L is an integer from 6 to 100, N and M are integers from 0 to 2L, with the proviso that either N or M is at least 2; XN and XM being amino acid sequences not occurring at this position and in this constellation with PeptideL and a polycationic substance.
AU2001267349A 2000-04-14 2001-04-17 Pharmaceutical preparations comprising modified peptides Abandoned AU2001267349A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT6572000 2000-04-14
AT657/2000 2000-04-14
PCT/EP2001/004313 WO2001078767A2 (en) 2000-04-14 2001-04-17 Pharmaceutical preparations comprising modified peptides

Publications (1)

Publication Number Publication Date
AU2001267349A1 true AU2001267349A1 (en) 2001-10-30

Family

ID=3678333

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001267349A Abandoned AU2001267349A1 (en) 2000-04-14 2001-04-17 Pharmaceutical preparations comprising modified peptides

Country Status (7)

Country Link
US (1) US20030095979A1 (en)
EP (1) EP1272215B1 (en)
JP (1) JP2003531128A (en)
AT (1) ATE375169T1 (en)
AU (1) AU2001267349A1 (en)
DE (1) DE60130877T2 (en)
WO (1) WO2001078767A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410173B (en) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh ANTIQUE COMPOSITION
WO2003047602A1 (en) * 2001-12-07 2003-06-12 Intercell Ag Immunostimulatory oligodeoxynucleotides
EP1523557A2 (en) 2002-07-24 2005-04-20 Intercell AG Antigens encoded by alternative reading frame from pathogenic viruses
EP2402026A3 (en) 2002-09-13 2012-04-18 Intercell AG Method for isolating hepatitis C virus peptides
DK1601770T3 (en) 2003-03-04 2009-11-02 Intercell Ag ANTIGENES OF THE STREPTOCOCCUS PYOGENES
WO2004084938A1 (en) 2003-03-24 2004-10-07 Intercell Ag Improved vaccines
AU2004226262A1 (en) 2003-03-31 2004-10-14 Intercell Ag Staphylococcus epidermidis antigens
EP2311989A1 (en) 2003-04-15 2011-04-20 Intercell AG S. pneumoniae antigens
JP2007535894A (en) 2003-05-07 2007-12-13 インターツェル・アクチェンゲゼルシャフト Streptococcus agalactier antigen I + II
CN102304527A (en) 2003-05-30 2012-01-04 英特塞尔股份公司 Enterococcus antigens
PL1648502T3 (en) 2003-07-11 2011-05-31 Intercell Ag Hcv vaccines
DE602005015605D1 (en) * 2004-10-29 2009-09-03 Intercell Ag HCV VACCINATE FOR CHRONIC HCV PATIENTS
EP1827471B1 (en) * 2004-11-09 2011-01-12 Celtek Bioscience, Llc. Composition and method for increasing apoptosis in cancer cells
EP2287189A1 (en) 2006-07-07 2011-02-23 Intercell AG Small Streptococcus pyogenes antigens and their use
CA2661224A1 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
EP1923069A1 (en) 2006-11-20 2008-05-21 Intercell AG Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
EP2266592A3 (en) 2007-01-12 2012-08-08 Intercell AG Protective proteins of S. agalactiae, combinations thereof and methods of using the same
CA2685805A1 (en) 2007-05-02 2008-11-13 Intercell Ag Klebsiella antigens
EP2167530A2 (en) 2007-06-18 2010-03-31 Intercell AG Chlamydia antigens
US8241643B2 (en) 2008-03-17 2012-08-14 Intercell Ag Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
US20130243779A1 (en) 2009-02-05 2013-09-19 Intercell Ag Peptides protective against e. faecalis, methods and uses relating thereto
EP2405938A2 (en) 2009-02-13 2012-01-18 Intercell AG Nontypable haemophilus influenzae antigens
WO2012139094A2 (en) 2011-04-08 2012-10-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of developing a vaccine using peptide-poly ic complexes
EP2915543B1 (en) 2014-03-04 2018-05-09 Albert-Ludwigs-Universität Freiburg Polypeptides derived from Enterococcus and their use for vaccination and the generation of therapeutic antibodies
EP3363459A1 (en) 2017-02-17 2018-08-22 Alexander Klimka Polypeptide epitopes of s. aureus and respective monoclonal antibodies for the treatment of infections and immune-diagnosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726292A (en) * 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5824315A (en) * 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules
WO1996037107A1 (en) * 1995-05-23 1996-11-28 The Scripps Research Institute Antigen-specific activation of unprimed cd8+ t cells
DK0836482T3 (en) * 1995-05-24 2003-02-17 Hawaii Biotech Group Subunit vaccine against flavivirus infection
AU724399B2 (en) * 1995-08-18 2000-09-21 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies

Also Published As

Publication number Publication date
EP1272215B1 (en) 2007-10-10
ATE375169T1 (en) 2007-10-15
JP2003531128A (en) 2003-10-21
WO2001078767A2 (en) 2001-10-25
DE60130877D1 (en) 2007-11-22
WO2001078767A3 (en) 2002-02-28
US20030095979A1 (en) 2003-05-22
DE60130877T2 (en) 2008-07-17
EP1272215A2 (en) 2003-01-08

Similar Documents

Publication Publication Date Title
AU2001267349A1 (en) Pharmaceutical preparations comprising modified peptides
AU633913B2 (en) Novel tnf-inhibit proteins and their preparation
IL92853A0 (en) Human insulin analogues,their preparation and pharmaceutical compositions containing them
AP2000001905A0 (en) Peptide compositions and formulations and use of same.
EP1884247A3 (en) Gastrin compositions and formulations, and methods of use and preparation
CA2265900A1 (en) Improved solid-phase peptide synthesis and agent for use in such synthesis
KR880009045A (en) Anticoagulant Peptides
AU2003264514A1 (en) Wt1 substitution peptides
PH12012502372A1 (en) Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
Shinkai et al. Amino acid sequence of cytochrome c 3 from Desulfovibrio vulgaris, Miyazaki
HK1160778A1 (en) Pharmaceutical composition comprising an analgesic peptide
NZ333606A (en) Isolated peptides derived from MAGE-2
EP1319023B8 (en) An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
WO1999040113A3 (en) Lipopeptides containing an interferon fragment and uses thereof in pharmaceutical compositions
CA2002924A1 (en) Anti-Thrombins
CA2026376A1 (en) Anticoagulant peptides
AU5776799A (en) Modified hcv peptide vaccines
Miura et al. Isolation and amino acid sequences of two trypsin inhibitors from the seeds of bitter gourd (Momordica charantia)
CA2423004A1 (en) Peptide inhibitors of hiv entry
EP1908781A3 (en) Modulation of immune response and methods based thereon
WO2003097677A3 (en) Novel peptide compositions and the use thereof, in particular, in the preparation of active pharmaceutical compositions against the hepatitis c virus
WO1999057262A3 (en) Peptide binding to metal ions
CA2375224A1 (en) Human antithrombin variants
AU1783900A (en) Topoisomerase ii inhibitor
AU2003259309A1 (en) Peptides having affinity for a phospholipid and uses